Clark, Gary M <br/><br/>
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.  [electronic resource] 

 -  Clinical lung cancer  May 2006 
 - 389-94 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1525-7304 
<br/><br/><label>Standard No.: </label>10.3816/clc.2006.n.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Canada--epidemiology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--therapeutic use<br/>Quinazolines--therapeutic use<br/>Retrospective Studies<br/>Risk Factors<br/>Smoking--adverse effects<br/>Survival Analysis